Effective treatment for geographic atrophy (GA) associated with age-related macular degeneration remains an elusive and unmet need in ophthalmology. A number of potential therapeutic agents1,2 are currently under evaluation at various stages of investigation including phase 3 clinical trials. Even if these agents prove to be effective, it appears that they can at best slow but not stop the progression of the disease. However, slowing progression may be a remarkable and meaningful outcome if the atrophy is nonfoveal and the rate of progression is slowed sufficiently compared with the patient’s longevity.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sadda SR, Sarraf D. Therapeutic Margin for Geographic Atrophy: The Race Between Longevity and Disease Progression. JAMA Ophthalmol. 2021;139(7):751–752. doi:10.1001/jamaophthalmol.2021.1414
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: